Anika Therapeutics Stock Price, News & Analysis (NASDAQ:ANIK) $22.48 +0.51 (+2.32%) (As of 12/7/2023 ET) Add Compare Share Share Today's Range$21.84▼$22.5950-Day Range$18.47▼$22.7552-Week Range$16.54▼$32.33Volume68,194 shsAverage Volume118,644 shsMarket Capitalization$329.13 millionP/E RatioN/ADividend YieldN/APrice Target$25.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Anika Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside13.4% Upside$25.50 Price TargetShort InterestHealthy3.44% of Float Sold ShortDividend StrengthN/ASustainability-1.70Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.45) to ($0.16) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.96 out of 5 starsMedical Sector549th out of 960 stocksMedical Instruments & Supplies Industry6th out of 8 stocks 2.3 Analyst's Opinion Consensus RatingAnika Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $25.50, Anika Therapeutics has a forecasted upside of 13.4% from its current price of $22.48.Amount of Analyst CoverageAnika Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.44% of the float of Anika Therapeutics has been sold short.Short Interest Ratio / Days to CoverAnika Therapeutics has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Anika Therapeutics has recently decreased by 7.53%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAnika Therapeutics does not currently pay a dividend.Dividend GrowthAnika Therapeutics does not have a long track record of dividend growth. Previous Next 3.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAnika Therapeutics has received a 50.41% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Synthetic bone grafts", "Medical splints", and "Medical screws" products. See details.Environmental SustainabilityThe Environmental Impact score for Anika Therapeutics is -1.70. Previous Next 1.1 News and Social Media Coverage Search Interest2 people have searched for ANIK on MarketBeat in the last 30 days. MarketBeat Follows6 people have added Anika Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Anika Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.85% of the stock of Anika Therapeutics is held by insiders.Percentage Held by Institutions90.79% of the stock of Anika Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Anika Therapeutics are expected to grow in the coming year, from ($0.45) to ($0.16) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Anika Therapeutics is -13.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Anika Therapeutics is -13.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAnika Therapeutics has a P/B Ratio of 1.15. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Anika Therapeutics Stock (NASDAQ:ANIK)Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and bone preserving joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief; and Hyvisc, a molecular weight injectable HA veterinary product. The company's joint preservation and restoration product family comprises 150 bone preserving joint technology products, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and orthopedic regenerative solutions, including Hyalofast and Tactoset. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including adhesion barrier, advanced wound care, ear, nose, and throat products, as well as ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.Read More ANIK Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ANIK Stock News HeadlinesNovember 29, 2023 | msn.comFirst surgeries testing rotator cuff augmentation implant carried out in FloridaNovember 5, 2023 | finance.yahoo.comAnika Therapeutics, Inc. (NASDAQ:ANIK) Q3 2023 Earnings Call TranscriptDecember 8, 2023 | Edge On The Street (Ad)The Battery Metal Nobody Told You AboutAccording to McKinsey and Company, the battery storage market is growing rapidly, especially with the transition to clean, renewable energy. Lithium-ion batteries still grab most of the headlines. But analysts now call safe and long-lasting batteries made with vanadium "the future of battery tech." November 4, 2023 | markets.businessinsider.comAnika Therapeutics Receives Buy Rating Based on Strong Q3 Performance and Positive 2023 OutlookNovember 3, 2023 | finance.yahoo.comQ3 2023 Anika Therapeutics Inc Earnings CallNovember 2, 2023 | finance.yahoo.comAnika Reports Third Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance on Growing Momentum Across the BusinessNovember 1, 2023 | msn.comAnika Therapeutics Q3 2023 Earnings PreviewOctober 23, 2023 | finance.yahoo.comAnika Therapeutics, Inc. (NASDAQ:ANIK) is favoured by institutional owners who hold 66% of the companyDecember 8, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.October 6, 2023 | finance.yahoo.comInvestors in Anika Therapeutics (NASDAQ:ANIK) have unfortunately lost 52% over the last five yearsSeptember 19, 2023 | finance.yahoo.comAnika Announces the Full Market Release of the RevoMotion™ Reverse Shoulder Arthroplasty System during the 2023 Orthopaedic Summit: Evolving Technologies (OSET) Annual MeetingSeptember 16, 2023 | finanznachrichten.deAnika Therapeutics Inc.: Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 1, 2023 | finance.yahoo.comDown -20.42% in 4 Weeks, Here's Why You Should You Buy the Dip in Anika (ANIK)August 17, 2023 | finance.yahoo.comCaligan Partners LP Boosts Stake in Anika Therapeutics IncAugust 17, 2023 | marketwatch.comAnika Rotator-Cuff Treatment May Launch in 1Q Following Final FDA ApprovalAugust 17, 2023 | finance.yahoo.comAnika Receives 510(k) Clearance for Integrity™ Implant System, a Regenerative Hyaluronic Acid-Based Patch System for Augmentation of Rotator Cuff RepairsAugust 14, 2023 | msn.comBarrington Research Upgrades Anika Therapeutics (ANIK)August 11, 2023 | finance.yahoo.comAnika Therapeutics, Inc.'s (NASDAQ:ANIK) Intrinsic Value Is Potentially 92% Above Its Share PriceAugust 10, 2023 | msn.comStephens & Co. Maintains Anika Therapeutics (ANIK) Equal-Weight RecommendationAugust 9, 2023 | finance.yahoo.comQ2 2023 Anika Therapeutics Inc Earnings CallAugust 9, 2023 | finanznachrichten.deAnika Therapeutics Inc.: Anika Reports Second Quarter 2023 Financial ResultsAugust 3, 2023 | finance.yahoo.comAdvanced wound care market to grow by USD 4,020.97 million from 2022 to 2027|The increasing volume of surgical procedures drives growth - TechnavioJuly 12, 2023 | finance.yahoo.comAnika Showcases Highly Differentiated Joint Preservation and Restoration Portfolio at the 2023 AOSSM Annual MeetingMay 31, 2023 | msn.comStephens & Co. Reiterates Anika Therapeutics (ANIK) Equal-Weight RecommendationMay 30, 2023 | finance.yahoo.comAnika Completes Enrollment in Hyalofast® U.S. Pivotal Phase III Study Achieving Key MilestoneMay 17, 2023 | marketwatch.comHemostatic Agents Market Research | 2023-2030May 16, 2023 | finance.yahoo.comGlobal Osteoarthritis Therapeutics Market to Reach $15.8 Billion by 2030See More Headlines Receive ANIK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Anika Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/04/2021Today12/07/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/04/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Medical Instruments & Supplies Sub-IndustryHealth Care Supplies SectorMedical Current SymbolNASDAQ:ANIK CUSIP03525510 CIK898437 Webwww.anikatherapeutics.com Phone(781) 457-9000Fax781-305-9720Employees345Year Founded1992Price Target and Rating Average Stock Price Target$25.50 High Stock Price Target$28.00 Low Stock Price Target$23.00 Potential Upside/Downside+13.4%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.69) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,860,000.00 Net Margins-15.05% Pretax Margin-17.46% Return on Equity-3.32% Return on Assets-2.74% Debt Debt-to-Equity RatioN/A Current Ratio5.59 Quick Ratio4.03 Sales & Book Value Annual Sales$163.31 million Price / Sales2.02 Cash Flow$0.50 per share Price / Cash Flow44.59 Book Value$19.55 per share Price / Book1.15Miscellaneous Outstanding Shares14,641,000Free Float13,785,000Market Cap$329.13 million OptionableOptionable Beta0.73 Social Links 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Cheryl Renee Blanchard Ph.D. (Age 59)President, CEO & Director Comp: $1.31MMr. Michael L. Levitz (Age 49)Executive VP, CFO & Treasurer Comp: $710.6kMr. David Colleran J.D. (Age 51)Executive VP, General Counsel & Corporate Secretary Comp: $664.54kMs. Anne Nunes (Age 54)Senior VP & COO Mr. Ian W. McLeodVP & Chief Accounting OfficerMr. Mark Namaroff (Age 60)Executive Director of Investor Relations & Corporate Communications Mr. James ChaseSenior Vice President of International Sales & MarketingMr. Ben JosephVice President of Commercial & Corporate DevelopmentMs. Lisa FunicielloVice President of Human ResourcesMore ExecutivesKey CompetitorsOrthofix MedicalNASDAQ:OFIXAccurayNASDAQ:ARAYAngioDynamicsNASDAQ:ANGOSurmodicsNASDAQ:SRDXOraSure TechnologiesNASDAQ:OSURView All CompetitorsInstitutional OwnershipAmerican Century Companies Inc.Bought 2,595 shares on 11/30/2023Ownership: 0.079%Deutsche Bank AGSold 73,025 shares on 11/24/2023Ownership: 0.054%Connors Investor Services Inc.Bought 2,500 shares on 11/22/2023Ownership: 0.073%Tudor Investment Corp Et AlBought 36,031 shares on 11/16/2023Ownership: 0.246%Royal Bank of CanadaSold 877 shares on 11/15/2023Ownership: 0.340%View All Institutional Transactions ANIK Stock Analysis - Frequently Asked Questions Should I buy or sell Anika Therapeutics stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Anika Therapeutics in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ANIK shares. View ANIK analyst ratings or view top-rated stocks. What is Anika Therapeutics' stock price target for 2024? 2 equities research analysts have issued 12-month target prices for Anika Therapeutics' shares. Their ANIK share price targets range from $23.00 to $28.00. On average, they anticipate the company's share price to reach $25.50 in the next twelve months. This suggests a possible upside of 13.4% from the stock's current price. View analysts price targets for ANIK or view top-rated stocks among Wall Street analysts. How have ANIK shares performed in 2023? Anika Therapeutics' stock was trading at $29.60 at the beginning of 2023. Since then, ANIK stock has decreased by 24.1% and is now trading at $22.48. View the best growth stocks for 2023 here. Are investors shorting Anika Therapeutics? Anika Therapeutics saw a drop in short interest in the month of November. As of November 15th, there was short interest totaling 489,100 shares, a drop of 7.5% from the October 31st total of 528,900 shares. Based on an average daily trading volume, of 203,300 shares, the short-interest ratio is presently 2.4 days. Currently, 3.4% of the shares of the stock are sold short. View Anika Therapeutics' Short Interest. When is Anika Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, March 4th 2024. View our ANIK earnings forecast. How were Anika Therapeutics' earnings last quarter? Anika Therapeutics, Inc. (NASDAQ:ANIK) issued its quarterly earnings results on Thursday, November, 4th. The biotechnology company reported $0.05 earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.26. The biotechnology company had revenue of $39.54 million for the quarter, compared to analyst estimates of $36.45 million. Anika Therapeutics had a negative net margin of 15.05% and a negative trailing twelve-month return on equity of 3.32%. During the same period in the prior year, the business earned ($0.45) EPS. What other stocks do shareholders of Anika Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Anika Therapeutics investors own include Alibaba Group (BABA), Broadcom (AVGO), Gilead Sciences (GILD), Micron Technology (MU), Skyworks Solutions (SWKS), Tesla (TSLA), Advanced Micro Devices (AMD), CVS Health (CVS), Enterprise Products Partners (EPD) and Ligand Pharmaceuticals (LGND). Who are Anika Therapeutics' major shareholders? Anika Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Trigran Investments Inc. (15.14%), Acadian Asset Management LLC (2.30%), Ameriprise Financial Inc. (1.67%), Northern Trust Corp (1.00%), Charles Schwab Investment Management Inc. (0.78%) and Capital Management Corp VA (0.58%). Insiders that own company stock include Cheryl R Blanchard, David Colleran, Jeffery S Thompson, John B Henneman III, Michael L Levitz and Raymond J Land. View institutional ownership trends. How do I buy shares of Anika Therapeutics? Shares of ANIK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:ANIK) was last updated on 12/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anika Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.